Pharma Stock Soars 9% After Signing ₹1,300 Cr Deal to Acquire Japanese CDMO Company

Synopsis: Small-Cap shares rose 9% after signing a deal to acquire Japan’s MicroBiopharm (MBJ) for about ₹1,300 crore via a wholly owned subsidiary. MBJ adds strengths in fermentation, biologics, and advanced biotech platforms like plasmid DNA and ADCs.

The shares of a Small-Cap company specialising in manufacturing fermentation-based Active Pharmaceutical Ingredients (APIs) and key pharmaceutical intermediates, are in focus as they announced the acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. (MBJ) through its wholly owned subsidiary, Themis Biosyn Japan Limited.

With a market capitalisation of Rs. 4,308.49 crores in the day’s trade, the shares of Gujarat Themis Biosyn Ltd rose upto 8.7 percent, making a high of Rs. 401.30 per share compared to its previous closing price of Rs. 368.85 per share.

What Happened

Gujarat Themis Biosyn Limited (GTBL), a leading pharmaceutical company with established expertise in fermentation-based intermediates and active pharmaceutical ingredients (APIs), has announced the signing of a definitive agreement to acquire 100% equity in MicroBiopharm Japan Co., Ltd. (MBJ), Japan. The acquisition will be carried out through a wholly owned subsidiary (SPV) to be incorporated in Japan, marking a significant step in GTBL’s global expansion strategy.

MBJ is a well-established Japanese company with over six decades of experience in fermentation and microbial-based research, development, and manufacturing of pharmaceuticals and speciality chemicals. 

Strategic Synergies and Business Strengthening

The acquisition is strategically aligned with GTBL’s long-term vision of transitioning into a technology-driven, globally integrated CDMO platform. MBJ brings complementary strengths, including precision fermentation technologies, proprietary platforms such as P450 enzyme libraries, plasmid DNA technology, and ADC conjugation capabilities. It also offers established relationships with global pharmaceutical companies, along with GMP-compliant manufacturing facilities that have undergone FDA and PMDA audits.

This integration is expected to create significant value through expanded technology access, cost efficiencies, and portfolio diversification. It will strengthen GTBL’s presence in oncology APIs, advanced biologics, and next-generation modalities while enhancing global market reach. Supported by experienced management teams with strong scientific backgrounds, the combined platform is positioned to accelerate innovation and long-term sustainable growth.

Deal Value and Financial Impact

The transaction is valued at approximately JPY 21.5 billion (around Rs. 1,300 crores) and will be funded through a mix of debt and equity. MBJ’s estimated revenue stands at about JPY 9.5 billion (around Rs. 570 crores) for FY26E. The deal is expected to be EPS accretive, meaning it should enhance earnings per share and create long-term value for GTBL shareholders after completion.

The acquisition will be executed through a wholly owned special purpose vehicle (SPV) to be incorporated in Japan. The transaction is expected to close during Q2FY27, subject to customary approvals and closing formalities.

Dr Sachin Patel, Managing Director of GTBL, stated that this acquisition is a key milestone in the company’s shift toward a next-generation, discovery-led CDMO platform. He highlighted that MBJ’s strong fermentation and biotechnology capabilities, along with its regulatory strengths and scalable infrastructure, will significantly enhance GTBL’s ability to serve global pharmaceutical customers across advanced and emerging therapeutic areas.

He further added that integrating MBJ’s platform with GTBL’s existing fermentation and process innovation strengths will help build a globally competitive, high-margin business. He also assured that MBJ’s existing leadership, management, and employees will be retained and supported as the combined entity grows and expands into new opportunities.

Can the Japan Deal Transform India’s Pharma CDMO Landscape?

GTBL’s acquisition of MicroBiopharm Japan Co., Ltd. (MBJ) for around Rs. 1,300 crores represents a major strategic shift from a fermentation-focused API player to a globally integrated, technology-driven CDMO platform. 

By bringing in MBJ’s six decades of expertise in fermentation, biologics, and small-molecule manufacturing, along with advanced technologies like plasmid DNA, P450 enzyme libraries, and ADC capabilities, GTBL significantly upgrades its scientific and manufacturing depth. This positions the company to compete in high-value, innovation-led segments of the global pharmaceutical value chain, not just commodity APIs.

If successfully integrated, the deal could also have wider implications for India’s CDMO landscape by demonstrating how Indian companies can acquire advanced capabilities from established global players to move up the value chain. 

The combination of GTBL’s cost-efficient manufacturing base in India and MBJ’s regulatory strength in Japan and global markets could create a more competitive, high-margin platform. This model may encourage similar cross-border acquisitions, accelerating India’s transition from a generic-focused industry to a more innovation- and service-driven CDMO ecosystem.

Financials & Others

The company’s revenue rose by 9.74 percent from Rs. 40 crores in December 2024 to Rs. 43 crores in December 2025. Meanwhile, Net profit declined from Rs. 13 crores to Rs. 12 crores in the same period.

The company shows strong profitability metrics, with a Return on Capital Employed (ROCE) of 27.3% and Return on Equity (ROE) of 21.7%, indicating efficient use of capital and solid returns for shareholders. It has also maintained a healthy long-term ROE track record of 31.5% over the last three years, reflecting consistent performance in generating profits from equity capital.

On the financial health side, the company maintains a low debt-to-equity ratio of 0.27, suggesting conservative leverage and lower financial risk. Additionally, its working capital cycle has improved significantly, reducing from 62.3 days to 45.6 days, which indicates better operational efficiency and faster conversion of resources into cash.

Gujarat Themis Biosyn Ltd is an India-based pharmaceutical company engaged in the development, manufacturing and marketing of fermentation-based pharmaceutical intermediates and APIs across key therapeutic segments in India. The company specialises in fermentation-based product development and continues to expand its presence across the Indian and global markets with a focus on building an integrated and scalable pharmaceutical platform.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Soars 9% After Signing ₹1,300 Cr Deal to Acquire Japanese CDMO Company appeared first on Trade Brains.